Epidermolysis bullosa (EBS) is a group of rare inherited skin diseases that unfortunately have no currently approved or known cure or treatment. InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) has developed INM-750 as the first therapy to specifically treat EBS. “Earlier this month, InMed filed an international Patent Cooperation Treaty application for intellectual and commercial protection of INM-750 and a cannabinoid-based therapy for EBS. This marks a significant milestone for the company, serving as validation for its efforts to develop new therapies based on cannabinoids and its unique approach to drug development. The company is using a proprietary bioinformatics assessment tool to identify what bioactive cannabis compounds can offer the optimal therapeutic benefits, with limited side effects and a proprietary biosynthesis technology to manufacture and test these compounds in biological systems via in vitro and in vivo experimentation. These proprietary systems and its drug development pipeline are the company’s core assets.”
To view the full article, visit: http://nnw.fm/6IxtN
InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary bioinformatics database assessment tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of CannabisNewsWire (CNW). NNB keeps you up-to-date on active US Public Companies complementary to CNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
Please see full disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer